Intensive Chemotherapy and Thoracic Irradiation as Induction Treatment in Limited-Stage Small-Cell Lung Cancer

2015 ◽  
pp. 155-162
Author(s):  
R. L. Souhami ◽  
C. M. Ash ◽  
H. M. Earl ◽  
P. G. Harper ◽  
D. Geddes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Induction Treatment ◽  
Intensive Chemotherapy ◽  
Small Cell Lung ◽  
Thoracic Irradiation ◽  
Limited Stage

Intensive chemotherapy and thoracic irradiation as induction treatment in small cell lung cancer (SCLC)

Lung Cancer ◽  
1989 ◽  
Vol 5 (1) ◽  
pp. 29-30
Author(s):  
R.L. Souhami ◽  
C.M. Ash ◽  
H.M. Earl ◽  
P.G. Harper ◽  
D. Geddes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Induction Treatment ◽  
Intensive Chemotherapy ◽  
Small Cell Lung ◽  
Thoracic Irradiation

Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer

2003 ◽  
Vol 56 (2) ◽  
pp. 355-359 ◽  
Author(s):  
Keith L Miller ◽  
Lawrence B Marks ◽  
Gregory S Sibley ◽  
Robert W Clough ◽  
Jennifer L Garst ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Once Daily ◽  
Thoracic Irradiation ◽  
Limited Stage

Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.

1993 ◽  
Vol 11 (5) ◽  
pp. 879-884 ◽  
Author(s):  
D H Johnson ◽  
A T Turrisi ◽  
A Y Chang ◽  
R Blum ◽  
P Bonomi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pilot Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Eastern Cooperative Oncology Group ◽  
Small Cell ◽  
Induction Treatment ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Limited Stage

PURPOSE This pilot study was undertaken to determine the efficacy and feasibility of alternating cisplatin and etoposide with multiple daily fractions of thoracic radiotherapy (TRT) in patients with limited-stage small-cell lung cancer (SCLC). PATIENTS AND METHODS Thirty-four SCLC patients received four courses of cisplatin (30 mg/m2/d x 3) plus etoposide (120 mg/m2/d x 3) (PE) every 3 weeks. TRT was administered twice daily (1.5 Gy per fraction) for 5 consecutive days in the week after cycles 1, 2, and 3 of chemotherapy (total TRT dose, 45 Gy). Patients who achieved a complete response (CR) received one course of late-intensification (LI) treatment consisting of cyclophosphamide (4 g/m2) and etoposide (900 mg/m2). Prophylactic cranial irradiation (PCI) was optional. RESULTS Nineteen of 32 assessable patients achieved a CR (59%) and 12 had a partial response (38%), for an overall response rate of 97% (95% confidence interval [CI], 84% to 99%). Median survival was 18 months, while 2-year progression-free survival was 47%. Leukopenia < or = 1,000/microL occurred in 12% of induction treatment cycles. Severe esophagitis was uncommon. Pulmonary fibrosis that was asymptomatic or minimally symptomatic was observed in eight patients (25%). There was one episode of adult respiratory distress syndrome (ARDS) during LI chemotherapy. Life-threatening neutropenia (< or = 500/microL) developed in all patients who underwent LI chemotherapy, with a median duration of 10 days (range, 8 to 19). Two patients died of sepsis during LI chemotherapy. CONCLUSION Alternating PE and TRT as performed in this trial is an effective brief induction regimen for limited-stage SCLC. However, this particular regimen did not appear to be substantially different in terms of efficacy or toxicity compared with regimens using concurrent chemotherapy and standard-fraction TRT. LI chemotherapy was associated with unacceptable toxicity and did not appear to have a favorable impact on survival.

Dose intensive chemotherapy for limited-stage (LS) small cell lung cancer (SCLC): A phase II study

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 7157-7157 ◽  
Author(s):  
K. Kubota ◽  
K. Yoh ◽  
S. Niho ◽  
K. Goto ◽  
H. Ohmatsu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Small Cell ◽  
Intensive Chemotherapy ◽  
Small Cell Lung ◽  
Limited Stage

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

1993 ◽  
Vol 11 (2) ◽  
pp. 336-344 ◽  
Author(s):  
N Murray ◽  
P Coy ◽  
J L Pater ◽  
I Hodson ◽  
A Arnold ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Combined Modality Therapy ◽  
Small Cell ◽  
Combined Modality Treatment ◽  
Small Cell Lung ◽  
Thoracic Irradiation ◽  
Limited Stage ◽  
Combined Modality

PURPOSE The importance of the timing of thoracic irradiation (TI) in the combined modality therapy of limited-stage small-cell lung cancer (SCLC) was assessed in a randomized trial. METHODS All 308 eligible patients received cyclophosphamide, doxorubicin, and vincristine (CAV) alternating with etoposide and cisplatin (EP) every 3 weeks for three cycles of each chemotherapy regimen. Patients randomized to early TI received 40 Gy in 15 fractions over 3 weeks to the primary site concurrent with the first cycle of EP (week 3), and late TI patients received the same radiation concurrent with the last cycle of EP (week 15). After completion of all chemotherapy and TI, patients without progressive disease received prophylactic cranial irradiation (25 Gy in 10 fractions over 2 weeks). RESULTS Although complete remission rates were not significantly different between the two arms, progression-free survival (P = .036) and overall survival (P = .008) were superior in the early TI arm. Patients in the late TI arm had a higher risk of brain metastases (P = .006). CONCLUSION The early administration of TI in the combined modality therapy of limited-stage SCLC is superior to late or consolidative TI.

Sign in / Sign up

Export Citation Format

Share Document